Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 5/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 5/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12861087 | 0.89 | MTNR1A (0.44) | MTNR1AMTNR1BACACBACACAPLA2G2C | |
| SCHEMBL18211583 | 0.84 | MTNR1A (0.39) | MTNR1AMTNR1BTDP1ACACBACACA | |
| SCHEMBL15856244 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BACACBACACAPLA2G2C | |
| SCHEMBL10027724 | 0.79 | TDP1 (0.48) | TDP1 | |
| SCHEMBL18211580 | 0.78 | TDP1 (0.39) | TDP1 | |
| SCHEMBL18866801 | 0.78 | TDP1 (0.32) | TDP1 | |
| SCHEMBL6124096 | 0.77 | TDP1 (0.47) | TDP1 | |
| SCHEMBL15905667 | 0.76 | TDP1 (0.39) | MTNR1AMTNR1BTDP1 | |
| SCHEMBL13091634 | 0.75 | MTNR1A (0.53) | MTNR1AMTNR1BACACBACACAPLA2G2C | |
| SCHEMBL8404918 | 0.75 | MTNR1A (0.44) | MTNR1AMTNR1BACACBACACAPLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177619-A1 | IN VITRO DIAGNOSTIC MARKERS COMPRISING CARBON NANOPARTICLES AND KITS | PITLAB LTD (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177619-A1 | IN VITRO DIAGNOSTIC MARKERS COMPRISING CARBON NANOPARTICLES AND KITS | CD63, LGALS3, MKI67 | MTNR1A 3163/4885MTNR1B 3382/4885TDP1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.